Metformin and the gastrointestinal tract

Diabetologia

Volumn 59, Issue 3, 2016, Pages 426-435

  McCreight, Laura J ^a   Bailey, Clifford J ^b   Pearson, Ewan R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

Bile acids; DPP 4; GLP 1; Gut intestine; Lactate; Metformin; Microbiome; OCT1; Review; Serotonin; Uptake

Indexed keywords

BILE ACID; GLUCAGON LIKE PEPTIDE 1; HISTAMINE; LACTIC ACID; METFORMIN; ORGANIC CATION TRANSPORTER 1; SEROTONIN;

ANAEROBIC METABOLISM; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TRANSPORT; ENDOCRINE FUNCTION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GUT BRAIN AXIS; HUMAN; INTESTINE ABSORPTION; INTESTINE FLORA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DRUG EFFECTS; METABOLISM; MICROBIOLOGY; MICROFLORA;

GASTROINTESTINAL TRACT; GLUCAGON-LIKE PEPTIDE 1; HUMANS; METFORMIN; MICROBIOTA;

EID: 84957440490     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3844-9     Document Type: Review

References (87)

1. Bailey CJ, Day C (1989) Traditional plant medicines as treatments for diabetes. Diabetes Care 12:553–564
2. Bailey CJ, Day C (2004) Metformin: its botanical background. Pract Diabetes Int 21:115–117
3. Inzucchi SI, Bergenstal RM, Buse JB et al (2015) Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58:429–442
4. Graham GG, Punt J, Arora M et al (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50:81–98
5. Innzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK (2014) Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 312:2668–2675
6. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865
7. Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CN, Pearson ER (2015) Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes 64:1786–1793
8. Zhou K, Donnelly L, Yang J et al (2014) Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes Endocrinol 2:481–487
9. Scheen AJ (1996) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 30:359–371
10. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF (1981) Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12:235–246
11. Marathe PH, Wen Y, Norton J, Greene DS, Barbhaiya RH, Wilding IR (2000) Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol 50:325–332
12. Wilcock C, Bailey CJ (1994) Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 24:49–57
13. Bailey CJ, Wilcock C, Scarpello JHB (2008) Metformin and the intestine. Diabetologia 51:1552–1553
14. Davidson J, Howlett H (2004) New prolonged-release metformin improves gastrointestinal tolerability. Br J Diabetes Vasc Dis 4:273–277
15. Buse JB, DeFronzo RA, Rosenstock J et al (2015) The primary glucose-lowering effect of metformin resides in the gut, not the circulation. Results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. doi:10.2337/dc15-0488
16. Proctor WR, Bourdet DL, Thakker DR (2008) Mechanisms underlying saturable intestinal absorption of metformin. Drug Metab Dispos 36:1650–1658
17. Koehler MR, Wissinger B, Gorboulev V, Koepsell H, Schmid M (1997) The two human organic cation transporter genes SLC22A1 and SLC22A2 are located on chromosome 6q26. Cytogenet Cell Genet 79:198–200
18. Koepsell H, Endou H (2004) The SLC22 drug transporter family. Pflugers Arch 447:666–676
19. Müller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M (2005) Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 70:1851–1860
20. Han TK, Proctor WR, Costales CL, Cai H, Everett RS, Thakker DR (2015) Four cation-selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayers. J Pharmacol Exp Ther 352:519–528
21. Han TK, Everett RS, Proctor WR et al (2013) Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes. Mol Pharmacol 84:182–189
22. Lee N, Duan H, Hebert MF, Liang CJ, Rice KM, Wang J (2014) Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands. J Biol Chem 289:27055–27064
23. Engel K, Zhou M, Wang J (2004) Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem 279:50042–50049
24. Engel K, Wang J (2005) Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol Pharmacol 68:1397–1407
25. Zhou M, Xia L, Wang J (2007) Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 35:1956–1962
26. Stage TB, Brøsen K, Christensen MM (2015) A comprehensive review of drug-drug interactions with metformin. Clin Pharmacokinet 54:811–824
27. Christensen MM, Højlund K, Hother-Nielsen O et al (2015) Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers. Eur J Clin Pharmacol 71:691–697
28. Christensen MM, Brasch-Andersen C, Green H et al (2011) The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics 21:837–850
29. Christensen MM, Brasch-Andersen C, Green H (2015) The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c: corrigendum. Pharmacogenet Genomics 25:48–50, Corrigendum
30. Chen S, Zhou J, Xi M et al (2013) Pharmacogenetic variation and metformin response. Curr Drug Metab 14:1070–1082
31. Zhou K, Donnelly LA, Kimber CH et al (2009) Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 58:1434–1439
32. Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2:683–693
33. Oh JR, Song HC, Chong A et al (2010) Impact of medication discontinuation on increased intestinal FDG accumulation in diabetic patients treated with metformin. AJR Am J Roentgenol 195:1404–1410
34. Capitanio S, Marini C, Sambuceti G, Morbelli S (2015) Metformin and cancer: technical and clinical implications for FDG-PET imaging. World J Radiol 7:57–60
35. 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging 35:95–99
36. Röder PV, Geillinger KE, Zietek TS, Thorens B, Koepsell H, Daniel H (2014) The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS One 9, e89977
37. +-d-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187–196
38. Sakar Y, Meddah B, Faouzi MA, Cherrah Y, Bado A, Ducroc R (2010) Metformin-induced regulation of the intestinal D-glucose transporters. J Physiol Pharmacol 61:301–307
39. Walker J, Jijon HB, Diaz H, Salehi P, Churchill T, Madsen KL (2005) 5-Aminoimidazole-4-carboxamide riboside (AICAR) enhances GLUT2-dependent jejunal glucose transport: a possible role for AMPK. Biochem J 385:485–491
40. Naftalin RJ (2014) Does apical membrane GLUT2 have a role in intestinal glucose uptake. F1000Res 3:304
41. Ait-Omar A, Monteiro-Sepulveda M, Poitou C et al (2011) GLUT2 accumulation in enterocyte apical and intracellular membranes: a study in morbidly obese human subjects and ob/ob and high fat-fed mice. Diabetes 60:2598–2607
42. Madiraju AK, Erion DM, Rahimi Y et al (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510:542–546
43. Davis TM, Jackson D, Davis WA, Bruce DG, Chubb P (2001) The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: the Fremantle Diabetes Study. Br J Clin Pharmacol 52:137–144
44. Bailey CJ, Wilcock C, Day C (1992) Effect of metformin on glucose metabolism in the splanchnic bed. Br J Pharmacol 105:1009–1013
45. Jackson RA, Hawa MI, Jaspan JB et al (1987) Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 36:632–640
46. Penicaud L, Hitier Y, Ferre P, Girard J (1989) Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine. Biochem J 262:881–885
47. Bailey CJ, Mynett KJ, Page T (1994) Importance of the intestine as a site of metformin-stimulated glucose utilization. Br J Pharmacol 112:671–675
48. Lalau JD, Lacroix C, Compagnon P et al (1995) Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 18:779–784
49. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA (1998) Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 338:265–266
50. Mannucci E, Ognibene A, Cremasco F et al (2001) Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese non-diabetic subjects. Diabetes Care 24:489–494
51. Green BD, Irwin N, Duffy NA, Gault VA, O’Harte FP, Flatt PR (2006) Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 547:192–199
52. Lindsay JR, Duffy NA, McKillop AM, Ardill J, O'Harte FP, Flatt PR, Bell PM (2005) Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes. Diabet Med 22:654–657
53. Cuthbertson J, Patterson S, O’Harte FP, Bell PM (2009) Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in type 2 diabetes. Diabet Med 26:649–654
54. Thondam SK, Cross A, Cuthbertson DJ, Wilding JP, Daousi C (2012) Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with type 2 diabetes mellitus. Diabet Med 29:e205–e210
55. Vardarli I, Arndt E, Deacon CF, Holst JJ, Nauck MA (2014) Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and “isoglycemic” intravenous glucose. Diabetes 63:663–674
56. Wu T, Thazhath SS, Bound MJ, Jones KL, Horowitz M, Rayner CK (2014) Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity? Diabetes Res Clin Pract 106:e3–e6
57. Fadini GP, Albiero M, Menegazzo L, de Kreutzenberg SV, Avogaro A (2012) The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients. Diabetes Obes Metab 14:518–522
58. Hinke SA, Kühn-Wache K, Hoffmann T, Pederson RA, McIntosh CH, Demuth HU (2002) Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 291:1302–1308
59. Yasuda N, Inoue T, Nagakura T et al (2002) Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 298:779–784
60. Mulherin AJ, Oh AH, Kim H, Grieco A, Lauffer LM, Brubaker PL (2011) Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology 152:4610–4619
61. Migoya EM, Bergeron R, Miller JL et al (2010) Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 88:801–808
62. Napolitano A, Miller S, Nicholls AW et al (2014) Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One 9, e100778
63. Kim MH, Jee JH, Park S, Lee MS, Kim KW, Lee MK (2014) Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling. J Endocrinol 220:117–128
64. Firneisz G, Varga T, Lengyel G et al (2010) Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One 5, e12226
65. Yi F, Sun J, Lim GE, Fantus IG, Brubaker PL, Jin T (2008) Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology 149:2341–2351
66. Lien F, Berthier A, Bouchaert E et al (2014) Metformin interferes with bile acid homeostasis through AMPK–FXR crosstalk. J Clin Invest 124:1037–1051
67. Thomas C, Gioiello A, Noriega L et al (2009) TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10:167–177
68. 3 receptors. Naunyn Schmiedebergs Arch Pharmacol 361:85–91
69. Yee SW, Lin L, Merski M et al (2015) Prediction and validation of enzyme and transporter off-targets for metformin. J Pharmacokinet Pharmacodyn 42:463–475
70. Duca FA, Côté CD, Rasmussen BA et al (2015) Metformin activates a duodenal AMPK-dependent pathway to lower hepatic glucose production in rats. Nat Med 21:506–511
71. Stepensky D, Friedman M, Raz I, Hoffman A (2002) Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos 30:861–868
72. Scarpello JH, Hodgson E, Howlett HC (1998) Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med 15:651–656
73. Carter D, Howlett HC, Wiernsperger NF, Bailey CJ (2003) Differential effects of metformin on bile salt absorption from the jejunum and ileum. Diabetes Obes Metab 5:120–125
74. Caspary WF, Zavada I, Reimold W, Deuticke U, Emrich D, Willms B (1977) Alteration of bile acid metabolism and vitamin-B12-absorption in diabetics on biguanides. Diabetologia 13:187–193
75. Carter D, Howlett HC, Wiernsperger NF, Bailey C (2002) Effects of metformin on bile salt transport by monolayers of human intestinal Caco-2 cells. Diabetes Obes Metab 4:424–427
76. Beysen C, Murphy EJ, Deines K et al (2012) Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 55:432–442
77. Zema MJ (2012) Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action. Core Evid 7:61–75
78. Qin J, Li Y, Cai Z et al (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490:55–60
79. Karlsson FH, Tremaroli V, Nookaew I et al (2013) Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498:99–103
80. Hur KY, Lee MS (2015) Gut microbiota and metabolic disorders. Diabetes Metab J 39:198–203
81. Tilg H, Moschen AR (2014) Microbiota and diabetes: an evolving relationship. Gut 63:1513–1521
82. Everard A, Belzer C, Geurts L et al (2013) Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 110:9066–9071
83. Zhang X, Shen D, Fang Z et al (2013) Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One 8, e71108
84. Forslund K, Hildebrand F, Nielsen T et al (2015) Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. doi:10.1038/nature15766
85. Lee H, Ko G (2014) Effect of metformin on metabolic improvement and gut microbiota. Appl Environ Microbiol 80:5935–5943
86. Shin NR, Lee JC, Lee HY et al (2014) An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63:727–735
87. Burton JH, Johnson M, Johnson J, Hsia DS, Greenway FL, Heiman ML (2015) Addition of a gastrointestinal microbiome modulator to metformin improves metformin tolerance and fasting glucose levels. J Diabetes Sci Technol 9:808–814